Clinical Trial Update: PK and Dose Escalation and Expansion Study of DST-2970 [Phase 1]

View source ↗

Summary

Phase 1 PK and dose-escalation/expansion study of DST-2970 in prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DST-2970

Snippet

Sponsor: DisperSol Technologies, LLC | Conditions: Prostate Cancer | Phase 1 | Status: TERMINATED